by MA Dimopoulos 2024 Cited by 32drugs, Proteasome inhibitors, Elotuzumab, Anti-CD38 Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and.
Antineoplastic, Anti-CD38 antibody Multiple myeloma [DS:H ] Monoclonal antibody CD38 [HSA:952] [KO:K ] hsa , Hematopoietic cell lineage
A Phase I/IIa Study of Human Anti-CD38 Antibody MOR in Relapsed/Refractory Multiple Myeloma Physiological Effects of Drugs. Central
A substance that binds to a protein called CD38, which is found on some types of blood cells and in high levels on some cancer cells, including myeloma cells. Anti-CD38 monoclonal antibody may block the CD38 protein and help the immune system kill cancer cells. Some anti-CD38 monoclonal antibodies are being used to treat multiple myeloma.
The reduction or loss in CD38 cell surface expression is an important mechanism involved in resistance to anti-CD38 MoAbs in Multiple Myeloma . Thus, we next wondered if CD38 induction following
Isatuximab is an anti-CD38 mAb intended to treat relapsed or refractory multiple myeloma. It entered in Phase II trials for multiple myeloma and T-cell
Daratumumab (Darzalex) for Myeloma Treatment Another drug, daratumumab (Darzalex), binds to the CD38 marker, which multiple myeloma cells
Anti-CD38 monoclonal antibodies are a treatment for multiple myeloma two anti-CD38 monoclonal antibodies approved by the Food and Drug
A substance that binds to a protein called CD38, which is found on some types of blood cells and in high levels on some cancer cells, including myeloma cells. Anti-CD38 monoclonal antibody may block the CD38 protein and help the immune system kill cancer cells. Some anti-CD38 monoclonal antibodies are being used to treat multiple myeloma.
Comments